BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Data from more than 2,600 agitation episodes collected
Related Questions
How will the database lock and upcoming results affect BXY's valuation in the short term?
What are the expectations for regulatory approval timelines based on the SERENITY trial data?
How does BioXcel's SERENITY trial compare to competitor pipelines targeting agitation in bipolar disorder and schizophrenia?